Literature DB >> 2355724

Consequences of current lipid guidelines for the Federal Republic of Germany.

L Kohlmeier1, H Hoffmeister.   

Abstract

According to the results of the first nationally representative population study in the Federal Republic of Germany (FRG) conducted in 1984-1986, a vast majority of the population have elevated cholesterol levels and undesirable low density lipoprotein (LDL) cholesterol levels. This problem increases with age in two dimensions, more individuals become hyperlipemic and those who were hyperlipemic develop more extreme pathologic values. Preliminary analyses suggest that the national profile in the FRG is worse than that of the USA. Based on the current recommendations of the national cholesterol education program of the USA, 23 million adults in the FRG should be receiving dietary advice for elevated lipid levels and 18 million persons should be in regular treatment programs. Consequently, implementation of such a national strategy and program would require the assembly and training of an adequate professional body of physicians and support staff in the diagnosis and treatment of hyperlipidemias.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2355724     DOI: 10.1007/bf01648898

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

1.  Management of hypercholesterolemia. Are preventive interventions advisable?

Authors:  A Leaf
Journal:  N Engl J Med       Date:  1989-09-07       Impact factor: 91.245

2.  Know your cholesterol: population screening.

Authors:  P Laemmle; L Unger; C McCray; M Geisler; M Chalin; R I Hardy; C J Glueck
Journal:  J Lab Clin Med       Date:  1988-11

3.  The evolution of mass atherosclerotic diseases: the rationale for primary prevention.

Authors:  H Blackburn
Journal:  Ann Clin Res       Date:  1988

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Impact of public education and continuing medical education on physician attitudes and behavior concerning cholesterol.

Authors:  L Block; S W Banspach; K Gans; C Harris; T M Lasater; R C Lefebvre; R A Carleton
Journal:  Am J Prev Med       Date:  1988 Sep-Oct       Impact factor: 5.043

6.  Effect of screening and referral on follow-up and treatment of high blood cholesterol levels.

Authors:  L Råstam; R V Luepker; P L Pirie
Journal:  Am J Prev Med       Date:  1988 Sep-Oct       Impact factor: 5.043

7.  Impact of national guidelines for cholesterol risk factor screening. The Framingham Offspring Study.

Authors:  P W Wilson; J C Christiansen; K M Anderson; W B Kannel
Journal:  JAMA       Date:  1989-07-07       Impact factor: 56.272

8.  Change in physician perspective on cholesterol and heart disease. Results from two national surveys.

Authors:  B Schucker; J T Wittes; J A Cutler; K Bailey; D R Mackintosh; D J Gordon; C M Haines; M E Mattson; R S Goor; B M Rifkind
Journal:  JAMA       Date:  1987-12-25       Impact factor: 56.272

9.  Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society.

Authors: 
Journal:  Eur Heart J       Date:  1987-01       Impact factor: 29.983

10.  A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study.

Authors:  D M DeLong; E R DeLong; P D Wood; K Lippel; B M Rifkind
Journal:  JAMA       Date:  1986-11-07       Impact factor: 56.272

View more
  2 in total

Review 1.  Fatty acid composition of the diet: impact on serum lipids and atherosclerosis.

Authors:  N Zöllner; F Tatò
Journal:  Clin Investig       Date:  1992-11

2.  A comparison of serum total cholesterol levels and their determinants between the Federal Republic of Germany and the United States.

Authors:  J Rehm; C Sempos; L Kohlmeier; G Myers; W Thefeld; E Gunter; M Thamm; R Dortschy; R Murphy; M Feinleib; H Hoffmeister
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.